Qulipta — Net revenues
Products & Services · Net revenuesAbbVie Qulipta — Net revenues remained flat by 0.0% to $288.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 43.3%, from $201.00M to $288.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, strong physician adoption, and effective commercial execution, while a decrease may signal increased competition, patent cliffs, or loss of market share.
Detailed definition
This metric represents the total gross sales of the specific pharmaceutical product line, adjusted for returns, allowanc...
Peer comparison
Comparable to branded pharmaceutical product revenue lines at peer companies, often benchmarked against therapeutic area market growth rates and consensus analyst expectations for drug-specific performance.
abbv_segment_qulipta_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $33.00M | $62.00M | $66.00M | $96.00M | $132.00M | $114.00M | $131.00M | $150.00M | $176.00M | $201.00M | $193.00M | $267.00M | $288.00M | $288.00M |
| QoQ Change | — | — | — | — | +87.9% | +6.5% | +45.5% | +37.5% | -13.6% | +14.9% | +14.5% | +17.3% | +14.2% | -4.0% | +38.3% | +7.9% | +0.0% |
| YoY Change | — | — | — | — | — | — | +190.9% | +112.9% | — | +98.5% | +56.3% | +33.3% | +76.3% | +47.3% | +78.0% | +63.6% | +43.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's qulipta — net revenues?
- AbbVie (ABBV) reported qulipta — net revenues of $288.00M in Q4 2025.
- How has AbbVie's qulipta — net revenues changed year-over-year?
- AbbVie's qulipta — net revenues increased by 43.3% year-over-year, from $201.00M to $288.00M.
- What does qulipta — net revenues mean?
- The total net sales generated by the specific pharmaceutical product line during the reporting period.